Empiriko Corporation, a biotech company that has developed a novel in vitro biomimetic platform to accelerate small molecule drug development with current focus on antiviral therapies. The company is also developing a point-of-care diagnostic platform for personalized immunologic/genetic biomarker and drug monitoring. The synergies between these platforms enables Empiriko to cost effectively accelerate drug development and customize patient treatment for improved clinical outcomes.